A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema (LUDIC)
An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Amiens, France, 80054
- Novartis Investigative Site
-
Angers, France, 49044
- Novartis Investigative Site
-
Besançon cedex, France, 25030
- Novartis Investigative Site
-
Bobigny, France, 93009
- Novartis Investigative Site
-
Bordeaux, France, 33000
- Novartis Investigative Site
-
Bordeaux, France, 33100
- Novartis Investigative Site
-
Caen, France, 14050
- Novartis Investigative Site
-
Cesson Sevigne, France, 35510
- Novartis Investigative Site
-
Clermont-ferrand, France, 63014
- Novartis Investigative Site
-
Créteil, France, 94000
- Novartis Investigative Site
-
Grenoble, France, 38000
- Novartis Investigative Site
-
Lille, France, 59037
- Novartis Investigative Site
-
Lyon, France, 69437
- Novartis Investigative Site
-
Lyon, France, 69275
- Novartis Investigative Site
-
Lyon, France, 69007
- Novartis Investigative Site
-
Lyon Cedex 04, France, 69317
- Novartis Investigative Site
-
Mantes la joile, France, 78201
- Novartis Investigative Site
-
Marseille, France, 13008
- Novartis Investigative Site
-
Marseille cedex 05, France, 13385
- Novartis Investigative Site
-
Melun, France, 77000
- Novartis Investigative Site
-
Montpellier, France, 34000
- Novartis Investigative Site
-
Montpellier, France, 34295
- Novartis Investigative Site
-
Nice, France, 06000
- Novartis Investigative Site
-
Nimes, France, 30029
- Novartis Investigative Site
-
Osny, France, 95520
- Novartis Investigative Site
-
Paris, France, 75006
- Novartis Investigative Site
-
Paris, France, 75015
- Novartis Investigative Site
-
Paris, France, 75007
- Novartis Investigative Site
-
Paris Cedex 19, France, 75940
- Novartis Investigative Site
-
Paris, Cedex 12, France, F-75571
- Novartis Investigative Site
-
Puilboreau, France, 17138
- Novartis Investigative Site
-
Reims, France, 51092
- Novartis Investigative Site
-
Rouen, France, 76100
- Novartis Investigative Site
-
Saint Brieuc, France, 22015
- Novartis Investigative Site
-
Saint Etienne, France, 42000
- Novartis Investigative Site
-
Saitnt Herblain, France, 44819
- Novartis Investigative Site
-
St Jean, France, 31240
- Novartis Investigative Site
-
St-Priest-en-Jarez, France, 42270
- Novartis Investigative Site
-
Strasbourg, France, 67000
- Novartis Investigative Site
-
Toulouse, France, 31077
- Novartis Investigative Site
-
Tours, France, 37044
- Novartis Investigative Site
-
Vandoeuvre les Nancy, France, 54511
- Novartis Investigative Site
-
Vannes, France, 56000
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients >18 years of age who have signed an informed consent
- Patients with Type 1 or Type 2 diabetes mellitus (according to ADA or WHO guidelines) with HbA1c not more than 10.0% at screening (Visit 1). Patients should be on diet, exercise, and/or pharmacological treatment for diabetes.
- Patients with visual impairment due to focal or diffuse DME in at least one eye
- Central Retinal thickness on OCT ≥ 250 microns in the central subfield
- BCVA score between 78 and 39 letters, inclusively, using ETDRS-like visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/160)
- Decrease in vision is due to DME and not due to other causes, in the opinion of the investigator
- Medication for the management of diabetes must have been stable within 3 months prior to randomization and is expected to remain stable during the course of the study.
Exclusion Criteria:
Ocular concomitant conditions/ diseases
- Concomitant conditions in the study eye which could, in the opinion of the investigator, prevent the improvement of visual acuity on study treatment
- Active intraocular inflammation (grade trace or above) in either eye
- Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye
- History of uveitis in either eye Systemic conditions or treatments
- Active systemic infection
- History of stroke < 3 months
- Renal failure requiring dialysis or renal transplant OR renal insufficiency with creatinine levels > 2.0 mg/dl
- Untreated diabetes mellitus
- Blood pressure systolic > 160 mmHg and diastolic > 100 mmHg
- Untreated hypertension
- Known hypersensitivity to ranibizumab or any component of the ranibizumab formulation Others
- Women of childbearing potential not using the contraception method(s) specified in this study (specify), as well as women who are breastfeeding
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ranibizumab
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
proportion of patients with a 10 letters gain on Best Corrected Visual Acuity (BCVA)
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
mean average change in BCVA from baseline
Time Frame: 6 months
|
6 months
|
|
if the letters gain after 2 injections is predictive from the letters gain at 6 months
Time Frame: 6 months
|
6 months
|
|
mean number of injections needed to obtain a 10 letters gain
Time Frame: 6 months
|
6 months
|
|
mean number of injections needed to obtain a stable visual acuity for three consecutive monthly assessments
Time Frame: 6 months
|
6 months
|
|
efficacy of ranibizumab IVT on Central Retinal Thickness (OCT)
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Eye Diseases
- Neurologic Manifestations
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Sensation Disorders
- Macular Edema
- Edema
- Vision, Low
- Vision Disorders
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
Other Study ID Numbers
- CRFB002DFR08
- 2010-023315-34 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.